

Effect of *Helicobacter pylori* infection on gastric epithelial proliferation in progression from normal mucosa to gastric carcinoma

LIU Wen-Zhong, ZHENG Xiong, SHI Yao, DONG Quan-Jiang and XIAO Shu-Dong

Subject headings helicobacter infections; gastric mucosa/microbiology; stomach neoplasms/microbiology; gastric mucosa/pathology

Abstract

AIM To study the effect of *Helicobacter pylori* (*H. pylori*) infection on gastric epithelial proliferation in the progression from normal mucosa to gastric carcinoma.

METHODS Gastric biopsy specimens from normal controls ($n=11$), superficial gastritis ($n=32$), atrophic gastritis with intestinal metaplasia ($n=83$), dysplasia ($n=25$) and gastric carcinoma ($n=10$) were studied by immunohistochemical staining of proliferating cell nuclear antigen (PCNA).

RESULTS The gastric epithelial proliferation, expressed as PCNA labeling index (LI)%, was progressively increased in successive stages from normal mucosa to gastric carcinoma regardless of *H. pylori* status. There was significant difference in PCNA LI% among all groups ($P<0.01$). The analysis pursuing the effect of *H. pylori* infection on gastric epithelial proliferation in the progression from normal mucosa to gastric carcinoma showed that in superficial gastritis and mild atrophic gastritis groups, PCNA LI% in *H. pylori* positive patients were 13.14 ± 1.6 and 19.68 ± 2.22 respectively, significantly higher than 6.95 ± 0.78 and 11.34 ± 1.89 in *H. pylori* negative patients ($P<0.01$); but there was no such difference in other groups ($P>0.05$).

CONCLUSION *H. pylori* infection causes increased gastric epithelial proliferation in the stages of superficial and mild atrophic gastritis and may play a part in triggering gastric carcinogenesis.

INTRODUCTION

Gastric carcinoma is one of the leading causes of malignancy-related death in China, and its etiology has not been fully elucidated. The epidemiological and histopathological studies have shown that *Helicobacter pylori* (*H. pylori*) infection is closely associated with gastric carcinogenesis^[1-5]. However, the mechanism and the stages in which *H. pylori* participates in the process of gastric carcinogenesis are largely unknown. An increase in epithelial cell proliferation is one of the earliest mucosa changes in the development of gastric cancer, and may serve as a risk indicator for it^[6,7]. The proliferation nuclear cell antigen (PCNA) expression is a reliable marker for evaluation of cell proliferation^[8,9]. In this study, we used PCNA as a marker to investigate the effect of *H. pylori* infection on gastric epithelial proliferation in the progression from normal mucosa to gastric carcinoma.

MATERIALS AND METHODS

Subjects

Archival gastric biopsy specimens used in this study were randomly selected from those kept in the pathological department of Shanghai Institute of Digestive Diseases between January and December 1996. The specimens were taken from 161 subjects, and the diagnosis was made based on the endoscopic and histological findings. Subjects were assigned to one of the following five study groups according to the histological diagnosis: Group 1, normal gastric mucosa, *H. pylori* negative; group 2, chronic superficial gastritis; group 3, chronic atrophic gastritis with intestinal metaplasia; group 4, dysplasia; and group 5, gastric carcinoma (intestinal type). The atrophy and intestinal metaplasia in gastric mucosa were graded as mild, moderate and severe respectively according to the criteria proposed in Sydney system, and scored 1, 2 and 3. Atrophic gastritis was usually accompanied by intestinal metaplasia, so the scores of atrophy and intestinal metaplasia in each patient were added up, and then further classified as mild for total score equal or less than 2, moderate for scores 3-4, and severe for scores more than 4. The patients with chronic gastritis accompanied by dysplasia all belonged to group 4.

Shanghai Second Medical University, Ren Ji Hospital, Shanghai Institute of Digestive Diseases, Shanghai 200001, China

LIU Wen Zhong, professor of internal medicine, gastroenterologist, having 30 papers published.

*Supported by the Shanghai Municipal Commission of Science and Technology, No.954119023.

Correspondence to: Dr. LIU Wen-Zhong, Shanghai Second Medical University, Ren Ji Hospital, Shanghai Institute of Digestive Diseases, Shanghai 200001, China

Tel. +86 • 21 • 63200874, Fax. +86 • 21 • 63730455

Received 1997-12-18

PCNA staining

PCNA staining of antral biopsy specimens was performed using immunohistochemical ABC method. Briefly, PCNA staining was proceeded, after deparaffinizing in xylene, clearing in ethanol, rehydrating through graded ethanol and washing in PBS. Endogenous peroxidase was blocked by 0.3% H₂O₂, and then washed slightly in PBS. The sections were preincubated with diluted normal goat serum, and then incubated with anti-PCNA antibody (PC10, mouse anti-human, DAKO Company) diluted 1:80 at 4°C overnight. After draining, the sections were incubated with a biotinylated anti-mouse IgG diluted 1:50 for 60min, then incubated with ABC working solution for 30min according to manufacturer's instruction (Sino-American Biotechnology Company). After another washing, the sections were incubated with 3-3'-diaminobenzidine tetrahydrochloride (DAB) solution under microscopic monitoring, and then counterstained with hematoxylin. The stained PCNA positive tissue (gastric polyp) sections served as positive controls. A negative control, where primary antibody was replaced by PBS, was also stained parallelly.

Analysis of gastric epithelial proliferative activity

PCNA positive cells were counted only in well oriented sections with visible entire gastric pits. A mean number of 10 pits were examined for each specimen, and greater than 500 cells were analysed. Labeling index per cent (LI%) was measured by counting the percentage of the number of PCNA positive cells of the total number of cells.

Identification of *H. pylori* infection

H. pylori was detected under microscopy on the histological sections stained with a modified Giemsa staining method.

Statistical analysis

LI% was compare among groups, and the significance was analysed using Student's *t* test for unpaired data, *P* values less than 0.05 were considered statistically significant.

RESULTS

Table 1 shows the demographic profile and *H. pylori* status in 161 subjects. Figure 1 shows PCNA LI% in the study groups regardless of *H. pylori* status. PCNA LI% in normal gastric mucosa, superficial gastritis, atrophic gastritis, dysplasia and gastric carcinoma group was 6.31 ± 1.67 ($\bar{x} \pm s$), 10.04 ± 1.32 , 17.11 ± 2.55 , 32.46 ± 4.16 and 46.05 ± 4.63 , respectively. PCNA LI% was progressively increased from normal mucosa to gastric carcinoma, and there was significant difference between the groups ($P < 0.01$).

Table 1 The demographic profile and *H. pylori* status in 161 subjects

Study groups	No. of patients	Femal/male	Average ages(yrs)	No. of Hp positive	No. of Hp negative
Normal gastric mucosa	11	2/9	44.5	0	11
Superficial gastritis	32	10/22	43.6	16	16
Atrophic gastritis					
Mild	32	11/21	42.1	16	16
Moderate	26	11/15	51.0	15	11
Severe	25	8/17	56.1	10	15
Dysplasia	25	7/18	53.2	13	12
Gastric Carcinoma	10	3/7	66.2	5	5

Figure 2 shows the PCNA LI% in the groups associated with *H. pylori* status. Atrophic gastritis group was further classified into mild, moderate and severe subgroups based on the scores of atrophy and intestinal metaplasia. In superficial gastritis and mild atrophic gastritis groups, PCNA LI% in *H. pylori* positive patients was 13.14 ± 1.6 and 19.68 ± 2.22 respectively, significantly higher than 6.95 ± 0.78 and 11.34 ± 1.89 in *H. pylori* negative patients ($P < 0.01$); but there was no such difference in other groups ($P > 0.05$).




Figure 1 PCNA LI% in the study groups from normal gastric mucosa to gastric carcinoma regardless of *H. pylori* status.




Figure 2 PCNA LI% in study groups associated with *H. pylori* status from normal mucosa to gastric carcinoma. AG=atrophic gastritis.

DISCUSSION

The etiology of gastric carcinoma has not been fully elucidated. In 1988, Correa^[10] proposed a human model of gastric carcinogenesis based on the epidemiological, pathological and clinical findings. He postulated that gastric cancer develops through a complex sequence of events from normal to superficial gastritis, atrophic gastritis, intestinal metaplasia, dysplasia and finally to intestinal type gastric carcinoma, and that the chronic gastritis in the first step in the progression to malignancy. This postulation was proved correct later by several studies^[11,12].

H. pylori is the primary etiological cause of chronic gastritis^[13,14], and is associated with a sixfold increased risk of gastric carcinoma^[2]. Long-term studies of *H. pylori* infection have provided evidence of a progression from *H. pylori* gastritis to atrophic gastritis, intestinal metaplasia, and dysplasia. *H. pylori* has been listed by the WHO as class 1 carcinogen for gastric cancer. But the exact mechanisms that *H. pylori* participates in gastric carcinogenesis are not clear.

Excessive cell proliferation increases the chance of spontaneous error of DNA replication, and potentiates the action of any carcinogen targeting DNA, and thereby enhances the risk of neoplastic transformation of cells^[15]. The assessment of epithelial cell proliferation as an indicator of risk has been validated in gastric carcinoma, even before *H. pylori* was found to be associated with chronic gastritis^[6]. Several recent studies have shown that *H. pylori* infection can promote gastric epithelial proliferation^[16,17] so that *H. pylori* infection links to increased risks of gastric carcinogenesis. But few studies have pursued the effect of *H. pylori* infection on gastric epithelial proliferation in the progression from normal mucosa to gastric carcinoma^[18].

Our results showed that gastric epithelial proliferative activity expressed as PCNA LI% increased progressively from normal mucosa to superficial gastritis, atrophic gastritis, dysplasia and gastric carcinoma, suggesting that increased gastric epithelial proliferation is associated with gastric precancerous changes and gastric cancer, and can be used as an indicator for evaluating the risk of gastric carcinogenesis.

The analysis of the effect of *H. pylori* infection on gastric epithelial proliferation in progression from normal mucosa to gastric carcinoma indicated that the increase in gastric epithelial proliferation associated with *H. pylori* infection was only seen in superficial gastritis and mild atrophic gastritis, and in other groups, there

was no significant difference in PCNA LI% between *H. pylori* positive and negative patients. The results suggested that *H. pylori* infection causes increased gastric epithelial proliferation primarily in the stages of superficial and mild atrophic gastritis, and it may not have so strong influence in the late stages of gastric carcinogenesis. There, *H. pylori* infection may be the precipitating factor in triggering gastric carcinogenesis.

Once *H. pylori* gastritis develops to the stage of gastric atrophy, the gastric acid secretion will decrease markedly, leading to changes in gastric bacterial flora, and subsequently promoted the endogenous formation of carcinogenic N-nitrosocompounds^[19,20], and gastric epithelial proliferation. This may explain why *H. pylori* infection has less effect on gastric epithelial proliferation in late stages of gastric carcinogenesis.

REFERENCES

- 1 Forman D, Newell DG, Fullerton F, Yarnell JWG, Stacey AR, Wald N *et al*. Association between infection with *Helicobacter pylori* and risk of gastric cancer: evidence from a prospective investigation. *BMJ*, 1991;302(6788):1302-1305
- 2 Eurogast Study Group. An international association between *Helicobacter pylori* infection and gastric cancer. *Lancet*, 1993;341(8857):1359-1362
- 3 Parsonnett J, Friedman GD, Vandersteen DP, Chang Y, Vogelmann JH, Orentreich N *et al*. *Helicobacter pylori* infection and risk of gastric cancer. *N Engl J Med*, 1991;325(16):1127-1131
- 4 Craanen ME, Blok P, Dekker W, Tytgat GNJ. *Helicobacter pylori* and early gastric cancer. *Gut*, 1994;35(10):1372-1374
- 5 Aska M, Kimura T, Kato M, Kudo M, Miki K, Ogoshi K *et al*. Possible role of *Helicobacter pylori* infection in early gastric cancer development. *Cancer*, 1994;73(11):2691-2694
- 6 Xu YL, Zheng ZT. Cell proliferation kinetics in chronic gastritis and gastric cancer. *Chin Med J*, 1984; 97(8): 526-532
- 7 Lipkin M. Biomarkers of increased susceptibility to gastrointestinal cancer: new application to studies of cancer prevention in human subjects. *Cancer Res*, 1988; 48(2):235-245
- 8 Hall PA, leivison Da, Woods AL, Yu CC, Kellock DB, Watkins JA *et al*. Proliferating cell nuclear antigen (PCNA) immunolocalization in some neoplasia. *J Pathol*, 1990;162(4):285-294
- 9 Yamada K, Yoshitaka K, Sato M and Ahnen DJ *et al*. Proliferating cell nuclear antigen in normal, and colonic epithelium in the rat. *Gastroenterology*, 1992; 103(1):160-167
- 10 Correa P. A human model of gastric carcinogenesis. *Cancer Res*, 1988;48(13): 3554-3560
- 11 Correa P. A human model of gastric carcinogenesis. *Cancer Res*, 1988;48(13): 3554-3560
- 12 Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G *et al*. Gastric precancerous process in a high risk population: Cohort follow-up. *Cancer Res*, 1990;50(15):4737-4740
- 13 Jiang SJ, Liu WZ, Zhang DZ, Shi Y, Xiao SD, Zhang ZH. Campylobacter-like organisms in chronic gastritis, peptic ulcer and gastric carcinoma. *Scand J Gastroenterol*, 1987;22(6):553-555
- 14 Wyatt JL. Histopathology of gastroduodenal inflammation: The impact of *Helicobacter pylori*. *Histopathology*, 1995;26(1):1-15
- 15 Ames BN, Gold LS. Too many rodent carcinogens: Mitogenesis increases mutagenesis. *Science*, 1990;249(4970):970-971
- 16 Fan XG, Kelleher D, Fan XI, Xia HX, Keeling PWN. *Helicobacter pylori* increases proliferation of gastric epithelial cells. *Gut*, 1996;38(1):19-22
- 17 Lynch DAF, Mapstone NP, Clarke AMT, Sobala GM, Jackson P, Morrison L *et al*. Cell proliferation in *Helicobacter pylori* associated gastritis and the effect of eradication therapy. *Gut*, 1995;36(3):346-350
- 18 Cahill RJ, Kilgallen C, Beattie S, Hamilton H, O'Morain C *et al*. Gastric epithelial cell kinetics in the progression from normal mucosa to gastric carcinoma. *Gut*, 1996;(2)28:177-181
- 19 Correa P. *Helicobacter pylori* and gastric carcinogenesis. *Am J Surg Pathol*, 1995;19(suppl 1):S37-43
- 20 Sobala GM, Pignatelli B, Schorah CJ, Bartsch H, Sanderson M, Dixon MF *et al*. Levels of nitrite, nitrate, nitroso compound, ascorbic and total bile acids in gastric juice of patients with and without precancerous conditions of the stomach. *Carcinogenesis*, 1991;12(2):193-198